Apogee Therapeutics (APGE) Stock Analysis

What Apogee Therapeutics does

Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.

Key metrics

ETFs linked to APGE

Broad-market and Healthcare sector ETFs an investor holding Apogee Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how APGE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Apogee Therapeutics?

Apogee Therapeutics trades under the ticker APGE on NASDAQ.

Which exchange is APGE listed on?

APGE is listed on NASDAQ.

What sector does Apogee Therapeutics operate in?

Apogee Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze APGE in a portfolio?

PortView shows APGE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.